231 related articles for article (PubMed ID: 27557520)
1. Synergistic effect of reduced polypeptide micelle for co-delivery of doxorubicin and TRAIL against drug-resistance in breast cancer.
Hu C; Gu F; Tai Z; Yao C; Gong C; Xia Q; Gao Y; Gao S
Oncotarget; 2016 Sep; 7(38):61832-61844. PubMed ID: 27557520
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
3. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
4. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
6. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
[TBL] [Abstract][Full Text] [Related]
7. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
8. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer.
Tang S; Yin Q; Zhang Z; Gu W; Chen L; Yu H; Huang Y; Chen X; Xu M; Li Y
Biomaterials; 2014 Jul; 35(23):6047-59. PubMed ID: 24797883
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
11. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
[TBL] [Abstract][Full Text] [Related]
12. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer.
Zhou Y; Wang S; Ying X; Wang Y; Geng P; Deng A; Yu Z
Int J Nanomedicine; 2017; 12():6153-6168. PubMed ID: 28883726
[TBL] [Abstract][Full Text] [Related]
14. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy.
Yao C; Liu J; Wu X; Tai Z; Gao Y; Zhu Q; Li J; Zhang L; Hu C; Gu F; Gao J; Gao S
J Control Release; 2016 Jun; 232():203-14. PubMed ID: 27126903
[TBL] [Abstract][Full Text] [Related]
15. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
16. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
17. Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles.
Wang J; Ma W; Tu P
Macromol Biosci; 2015 Sep; 15(9):1252-61. PubMed ID: 25981672
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
19. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]